141 related articles for article (PubMed ID: 15722788)
1. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast.
Siziopikou KP; Khan S
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):14-8. PubMed ID: 15722788
[TBL] [Abstract][Full Text] [Related]
2. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
3. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer.
Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR
Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
5. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
6. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.
Liao N; Zhang GC; Liu YH; Li XR; Yao M; Xu FP; Li L; Wu YL
Pathol Res Pract; 2011 Jan; 207(1):1-7. PubMed ID: 21095069
[TBL] [Abstract][Full Text] [Related]
8. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
[TBL] [Abstract][Full Text] [Related]
9. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
10. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
12. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
13. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
14. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
Horimoto Y; Terao T; Tsutsumi Y; Tanabe M; Mogushi K; Hlaing MT; Sasaki R; Saeki H; Okazaki M; Sonoue H; Arakawa A; Saito M
Am J Surg Pathol; 2019 Sep; 43(9):1221-1228. PubMed ID: 31192864
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast.
Vos CB; Ter Haar NT; Peterse JL; Cornelisse CJ; van de Vijver MJ
J Pathol; 1999 Feb; 187(3):279-84. PubMed ID: 10398079
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.
Lee WY; Jin YT; Tzeng CC
Anticancer Res; 1996; 16(5A):3007-12. PubMed ID: 8917421
[TBL] [Abstract][Full Text] [Related]
19. [Molecular protocol for HER2/neu analysis in breast carcinoma].
Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
[TBL] [Abstract][Full Text] [Related]
20. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
